No Data
A Great Week That Adds to Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) One-year Returns, Institutional Investors Who Own 56% Must Be Happy
Express News | Day One Biopharmaceuticals Inc : JP Morgan Adds Stock to Its Analyst Focus List
Express News | JP Morgan Maintains Overweight on Day One Biopharmaceutical, Lowers Price Target to $36
Express News | Day One Biopharmaceuticals Inc : JP Morgan Cuts Target Price to $36 From $38
Day One Biopharmaceuticals | 10-Q: Q2 2024 Earnings Report
Day One Biopharma Draws Double Upgrade at BofA on Ojemda Potential